Last reviewed · How we verify
HX009
At a glance
| Generic name | HX009 |
|---|---|
| Also known as | Recombinant humanized anti-CD47/PD-1 bifunctional antibody, anti-PD-1/CD47 infusion protein |
| Sponsor | Hangzhou Hanx Biopharmaceuticals, Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (PHASE1, PHASE2)
- HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid Tumours (PHASE1, PHASE2)
- Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors (PHASE1)
- The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies (PHASE1)
- Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HX009 CI brief — competitive landscape report
- HX009 updates RSS · CI watch RSS
- Hangzhou Hanx Biopharmaceuticals, Ltd. portfolio CI